Anti-PD1 therapy in patients with metastatic melanoma: A single centre experience
-
Altmetric Citations
Nguyen, Bella Hai; Robinson, E; Arora, A; Ali, Sayed
Description
Background: The introduction of anti-PD1 checkpoint inhibitors: pembrolizumab and nivolumab has changed the treatment landscape of stage IV melanoma. Clinical trials reported response rates between 21% and 32%.2 Grade 3-4 adverse events ranged between 5% and 14%.1,2 A single-center experience of safety and efficacy of pembrolizumab, or nivolumab in treating stage IV melanoma were analyzed in this presentation. Methods: Records of patients from The Canberra Hospital between January 1,...[Show more]
dc.contributor.author | Nguyen, Bella Hai | |
---|---|---|
dc.contributor.author | Robinson, E | |
dc.contributor.author | Arora, A | |
dc.contributor.author | Ali, Sayed | |
dc.coverage.spatial | Gold Coast, Australia | |
dc.date.accessioned | 2020-07-08T03:16:53Z | |
dc.date.created | August 3-5, 2016 | |
dc.identifier.isbn | 1743-7555 | |
dc.identifier.uri | http://hdl.handle.net/1885/205930 | |
dc.description.abstract | Background: The introduction of anti-PD1 checkpoint inhibitors: pembrolizumab and nivolumab has changed the treatment landscape of stage IV melanoma. Clinical trials reported response rates between 21% and 32%.2 Grade 3-4 adverse events ranged between 5% and 14%.1,2 A single-center experience of safety and efficacy of pembrolizumab, or nivolumab in treating stage IV melanoma were analyzed in this presentation. Methods: Records of patients from The Canberra Hospital between January 1, 2014 to January 30, 2016 receiving either nivolumab or pembrolizumab were reviewed retrospectively. Patients who received prior anti-CTLA4 inhibitor, BRAF-inhibitors, surgical metastatectomy or radiotherapy were also included in the analysis. Results: Forty patients with complete data were identified. Median duration of treatment was 5 months. Median age was 73 (37-88). All 40 patients had stage IV disease. One patient had stage M1a (2.5%), 16 patients stage M1b (40%) and 23 patients stage M1c (57.5%). Thirteen patients (32.5%) had brain metastases. Three patients (7.5%) had received prior BRAF inhibitors and twenty-two (55%) had received prior Ipilimumab. Two patients had complete response (5%), eight patients (20%) had partial response and eighteen had prior partial response and currently have stable disease (45%). The clinical response rate was 70%. Twelve patients (30%) had progressive disease. Twenty-two patients (55%) experienced any degree of adverse reactions but no patients experienced grade IV toxicity. There were five patients (12.5%) who had treatment discontinuation due to toxicity. The most common toxicities were pruritus, fatigue, generalized myalgia/arthralgia and rash. Rare side effects experienced included autoimmune neuropathy, pneumonitis and nephritis. Conclusions: Treatment of stage IV melanoma with pembrolizumab and nivolumab in our center had comparable safety and efficacy to the published literature. | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en_AU | |
dc.publisher | Wiley | |
dc.relation.ispartofseries | 2016 Annual Scientific Meeting (ASM) of the Medical Oncology Group of Australia Incorporated (MOGA) | |
dc.rights | © 2016 The Authors. Asia-Pacific Journal of Clinical Oncology © 2016 Wiley Publishing Asia Pty Ltd | |
dc.source | Asia-Pacific Journal of Clinical Oncology | |
dc.title | Anti-PD1 therapy in patients with metastatic melanoma: A single centre experience | |
dc.type | Conference paper | |
local.description.notes | Imported from ARIES | |
local.description.refereed | Yes | |
dc.date.issued | 2016 | |
local.identifier.absfor | 111207 - Molecular Targets | |
local.identifier.ariespublication | u5234101xPUB253 | |
local.publisher.url | https://www.wiley.com/en-gb | |
local.type.status | Published Version | |
local.contributor.affiliation | Nguyen, Bella Hai, The Canberra Hospital | |
local.contributor.affiliation | Robinson, E, Canberra Hospital | |
local.contributor.affiliation | Arora, A, Canberra Hospital | |
local.contributor.affiliation | Ali, Sayed, College of Health and Medicine, ANU | |
local.description.embargo | 2037-12-31 | |
local.bibliographicCitation.startpage | 65 | |
local.bibliographicCitation.lastpage | 65 | |
local.identifier.doi | 10.1111/ajco.12543 | |
local.identifier.absseo | 920102 - Cancer and Related Disorders | |
dc.date.updated | 2020-03-08T07:21:45Z | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Nguyen_Anti-PD1_therapy_in_patients_2016.pdf | 47.26 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator